Oramed Pharmaceuticals Inc
$ 4.30
0.00%
07 Aug - close price
- Market Cap 175,982,000 USD
- Current Price $ 4.30
- High / Low $ 4.38 / 4.28
- Stock P/E 1.65
- Book Value 5.82
- EPS 2.60
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE 0.58 %
- 52 Week High 5.19
- 52 Week Low 1.84
About
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Analyst Target Price
$6.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-19 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-27 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-10 |
| Reported EPS | 0.9128 | 0.25 | 1.13 | 0.31 | -0.19 | -0.2552 | -0.48 | 0.22 | 0.04 | 0.33 | -0.08 | -0.03 |
| Estimated EPS | None | -0.08 | -0.04 | -0.04 | -0.03 | 0.02 | -0.02 | -0.02 | 0.02 | -0.12 | -0.09 | -0.09 |
| Surprise | 0 | 0.33 | 1.17 | 0.35 | -0.16 | -0.2752 | -0.46 | 0.24 | 0.02 | 0.45 | 0.01 | 0.06 |
| Surprise Percentage | None% | 412.5% | 2925% | 875% | -533.3333% | -1376% | -2300% | 1200% | 100% | 375% | 11.1111% | 66.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.43 |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | |
|---|---|
| Payment Date | 2026-01-26 |
| Amount | $0.25 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORMP
2026-08-07 19:40:45
This article provides an earnings forecast for Oramed Pharmaceuticals Inc (ORMP), noting that no specific earnings forecast score is currently available, although the industry average is 8.10. It highlights an average price target of $3.25 based on zero analyst ratings, indicating a potential 40.13% upside. The article also includes a peer comparison without specific ratings for ORMP but lists ratings for other biotechnology and medical research companies.
2026-08-06 18:40:45
Oramed Pharmaceuticals (ORMP) is expected to release its Q2 2026 earnings after market close on Thursday, August 13th, with analysts forecasting earnings of $0.43 per share. The company's stock recently traded at $4.32, marking a 3.1% decline, and holds a "Hold" consensus rating. Recent insider activity includes sales by COO Joshua Hexter and CFO Avraham Gabay, while institutional investors hold 12.73% of the company.
2026-08-04 08:09:48
Oramed Pharmaceuticals will hold its 2026 annual stockholders meeting in Jerusalem on September 15, 2026. Shareholders will vote on the election of six directors, the ratification of Kesselman & Kesselman as the independent auditor, and a proposal to increase the 2019 long-term incentive plan share pool by 3,000,000 to 12,500,000 shares. Other items include advisory votes on executive compensation and the frequency of future pay votes.
2026-08-04 01:40:21
This article reports on an ARS SEC filing by ORAMED PHARMACEUTICALS INC. (ORMP) on August 3, 2026. The filing was accepted by the SEC EDGAR system at 04:06 PM on the same day. It provides company overview, stock rankings, latest news, and recent SEC filings for ORMP, noting a low filing impact and neutral sentiment according to AI analysis.
2026-07-31 07:40:30
This article provides a technical analysis of Oramed Pharmaceuticals Inc (ORMP), focusing on its support and resistance levels, key indicators, and moving averages. As of July 30, 2026, the stock's price momentum score is 4.06, ranking 299 in its industry, and it is currently trading between a resistance of $4.66 and a support of $3.75. The analysis indicates a "Neutral" signal based on moving averages and other technical indicators.
2026-07-31 02:41:26
Oramed Pharmaceuticals Inc. (ORMP) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The company is engaged in developing oral dosage forms for biological insulin and other proteins, leveraging its Protein Oral Delivery (POD) technology. Despite recent weak market performance, the stock exhibits strong fundamentals and is trading sideways, making it potentially suitable for range-bound swing trading.
